BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 249,388 shares, an increase of 49.2% from the December 15th total of 167,154 shares. Based on an average daily volume of 117,346 shares, the short-interest ratio is presently 2.1 days. Currently, 2.8% of the shares of the company are sold short. Currently, 2.8% of the shares of the company are sold short. Based on an average daily volume of 117,346 shares, the short-interest ratio is presently 2.1 days.

Institutional Investors Weigh In On BioCardia

A hedge fund recently bought a new stake in BioCardia stock. Cetera Investment Advisers purchased a new position in BioCardia, Inc. (NASDAQ:BCDA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 20,275 shares of the company’s stock, valued at approximately $40,000. Cetera Investment Advisers owned approximately 0.37% of BioCardia at the end of the most recent reporting period. Hedge funds and other institutional investors own 20.57% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of BioCardia to a “sell” rating in a research note on Saturday, November 1st. Zacks Research upgraded BioCardia to a “hold” rating in a research report on Tuesday, September 23rd. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of BioCardia in a report on Monday, September 22nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

BioCardia Stock Performance

Shares of BCDA stock opened at $1.40 on Friday. The company has a market capitalization of $14.85 million, a PE ratio of -0.95 and a beta of 0.56. BioCardia has a 52-week low of $1.00 and a 52-week high of $3.20. The business’s fifty day moving average is $1.34 and its 200 day moving average is $1.63.

BioCardia (NASDAQ:BCDA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. On average, sell-side analysts forecast that BioCardia will post -3.52 EPS for the current fiscal year.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.